A Study of Efficacy of Ambroxol Combined with Azithromycin in the Treatment of Children with Mycoplasma Pneumoniae Pneumonia
Objective To explore the efficacy of ambroxol combined with azithromycin in treating Mycoplasma pneumoniae pneumonia(MPP)in children.Methods 157 children with mycoplasma pneumonia who were treated in Suining Central Hospital from March,2019 to March,2022 were selected and divided into the study group(79 cases)and control group(78 cases)by the simple randomization method.All children were given conventional treatments,including relieving cough and asthma and oxygen inhalation.The control group was given azithromycin intravenous infusion,while the study group was given azithromycin combined with ambroxol for intravenous infusion.After 7 days of treatment,the clinical efficacy,clinical symptom improvement time,pulmonary function[maximum minute ventilation volume(MVV),peak expiratory flow(PEF),ratio of forced expiratory volume to forced vital capacity(FEV1/FVC)],immune function[immunoglobulins G,A,M,E(IgG,IgA,IgM,IgE)],serum inflammatory factors[serum high-sensitivity C-reactive protein(hs-CRP),human monocyte chemoattractant protein-4(MCP-4),serum interleukin-4(IL-4)],alveolar surfactant protein D(SP-D)and soluble B7-H3(sB7-H3)and adverse reactions were compared between the two groups.Results After treatment,the total effective rate of clinical efficacy(94.94％)in the study group was significantly higher than that in the control group(84.62％)(P＜0.05).The disappearance time of each clinical symptom and time of negative conversion of MP antibody in the study group were significantly shorter compared with those in the control group(P＜0.05).MVV,PEF and FEV1/FVC of the two groups were significantly increased(P＜0.05),and MVV,PEF and FEV1/FVC in the study group after treatment were significantly higher than those in the control group(P＜0.05).The IgG level of the two groups was significantly increased(P＜0.05),while the levels of IGA,IgM and IgE were significantly decreased(P＜0.05).After treatment,the IgG level in the study group was significantly higher than that in the control group(P＜0.05),while IgM and IgE levels were significantly lower than those in the control group(P＜0.05),but there was no statistical difference in IgA level between the groups after treatment(P＞0.05).Levels of hs-CRP,MCP-4 and IL-4 in both groups were significantly reduced(P＜0.01),and these levels were significantly lower in the study group(P＜0.01).Levels of SP-D and sB7-H3 were significantly lowered in both group(P＜0.01),and these two levels in the study group were significantly lower compared to the control group(P＜0.01).During treatment,there were no significant adverse reactions in the two groups.Conclusion Intravenous infusion of ambroxol combined with azithromycin has a significant effect in the treatment of MPP,and it can effectively improve pulmonary function and immune inflammatory status with few complications.
Mycoplasma pneumonia in childrenClinical symptomsImmune functionInflammatory factors
NETL
NSTL
万方数据
维普
